Physician profile
Hye Min Yang
NPI 1447839857
$3,782.61
in general payments reported to CMS, 2019-2025
22 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.26 · 2022: $522 · 2023: $1,028 · 2024: $1,173 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,215.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $855.11 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $662.00 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $587.50 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $430.05 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $373.93 | 2022-2025 | Minimed 780g, Minimed 770g |
| Amneal Pharmaceuticals LLC | $335.07 | 2022-2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $106.51 | 2023-2024 | Strensiq |
| Tandem Diabetes Care, INC. | $61.66 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $48.10 | 2025 | Yorvipath |
| Exeltis, USA INC. | $44.26 | 2021 | |
| Insulet Corporation | $43.12 | 2022-2025 | Omnipod |
| Kyowa Kirin, INC. | $27.31 | 2025 | |
| Averitas Pharma INC. | $25.00 | 2023 | Qutenza |
| Recordati_rare_diseases_inc. | $24.43 | 2025 | Isturisa |
| Avvisto Therapeutics, LLC | $24.41 | 2024 | Cycloset |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $23.16 | 2024 | Korlym |
| Rhythm Pharmaceuticals, INC. | $21.84 | 2025 | Imcivree |
| Chiesi USA, INC. | $20.08 | 2024 | Mycapssa |
| Amgen INC. | $18.71 | 2025 | Evenity |
| Endo Pharmaceuticals INC. | $18.48 | 2023 | Nascobal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.26 | 2024 | Cycloset |
| Bayer Healthcare Pharmaceuticals INC. | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hye Min Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.